Related Experiment Videos
Therapeutic targets in ischaemic heart disease
1University Department of Cardiovascular Studies, General Infirmary, Leeds, West Yorkshire, England.
Insights
Effective treatment of ischemic heart disease requires clear therapeutic targets. Calcium antagonists uniquely prevent cell necrosis by managing myocardial cytosolic calcium during ischemic episodes, offering a key advantage in managing this complex condition.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart disease (IHD) presents complex origins, pathology, and natural history, making complete patient profiling challenging.
- Pharmacotherapy for IHD aims to relieve symptoms like pain and fatigue, and address electrophysiological indicators of myocardial ischemia.
Purpose of the Study:
- To define the essential targets for pharmacotherapy in managing ischemic heart disease.
- To highlight the role of specific drug classes in addressing IHD's complex pathophysiology and long-term goals.
Main Methods:
- The study reviews the pathophysiological components of IHD, including myocardial contractile dysfunction and neuroendocrine system stimulation.
- It examines the role of pharmacotherapy in correcting these abnormalities and preventing disease progression.
Main Results:
- Relief of symptoms (pain, breathlessness, fatigue) and addressing electrophysiological signs of ischemia are primary pharmacotherapeutic goals.
- Calcium antagonists demonstrate a unique ability to prevent myocardial cell necrosis by inhibiting increases in cytosolic calcium during ischemic events.
Conclusions:
- Comprehensive treatment of IHD necessitates targeting symptomatic, pathological, and physiological aspects.
- Calcium antagonists offer a distinct mechanism for mitigating acute ischemic injury, differentiating them from other antianginal agents.
Abstract:
The adequate treatment of a disease syndrome is dependent upon a clear definition of the symptomatic, pathological, physiological and prognostic targets against which therapy is to be deployed. The syndromes of ischaemic heart disease, including angina pectoris, are complex in origin, pathology, pathophysiology and natural history, and a complete clinical profile is difficult, if not impossible, to achieve in individual patients. The prime goals of pharmacotherapy in ischaemic heart disease are easy to define, but difficult to accomplish in practice. Relief of pain, breathlessness and fatigue are the prime clinical targets for pharmacotherapy. In view of their sinister significance, the electrophysiological indications of myocardial ischaemia, whether symptomatic or silent, are also crucial targets towards which therapy must be directed. Ischaemic heart disease is accompanied by a wide variety of regional and global abnormalities of myocardial contractile function associated with widespread reflex stimulation of the peripheral vascular system and neuroendocrine systems. Primarily, drug therapy must be directed at correction of these pathophysiological components of the syndrome. Longer term but no less essential goals in the treatment of ischaemic heart disease are the prevention of the clinical sequelae of the syndrome and its progression. A natural sequel of coronary artery obstructive disease is successive thrombotic events and loss of myocardium. Calcium antagonists, by preventing the increase in myocardial cytosolic calcium during acute ischaemic episodes, defer cell necrosis; in this respect, they are unique among currently available antianginal drugs. With regard to progression, the prime pathological cause of ischaemic heart disease is coronary atheroma.(ABSTRACT TRUNCATED AT 250 WORDS)